Skip to main content
Clinical Trials/ACTRN12615000913572
ACTRN12615000913572
Completed
Phase 4

A pilot study to investigate the efficacy, feasibility and safety of once weekly injection of exenatide-LAR in addition to standard diabetes care on blood glucose control in indigenous Australians with type 2 diabetes living in remote communities

BakerIDI Heart and Diabetes Institute0 sites40 target enrollmentSeptember 2, 2015

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
BakerIDI Heart and Diabetes Institute
Enrollment
40
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 2, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
BakerIDI Heart and Diabetes Institute

Eligibility Criteria

Inclusion Criteria

  • Indigenous Australians with T2DM, BMI \> 25kg/m2 and HbA1c \> 7\.5%.

Exclusion Criteria

  • Pregnancy , childbearing potential, Type 1 diabetes, history of pancreatitis, history of heavy alcohol abuse, eGFR \< 45 45ml/min/1\.73m2

Outcomes

Primary Outcomes

Not specified

Similar Trials